

CardioComm Solutions, Inc. Announces Closing of Private Placement Equity Financing

Victoria, B.C., April 14, 2010 – CardioComm Solutions, Inc. (TSX-V: EKG) (“CardioComm” or the “Company”) today announced that it has closed its previously announced non-brokered private placement equity financing. Under the financing, the Company issued 10,000,000 units at a price of \$0.05 per unit for gross proceeds of \$500,000. Each unit was comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of \$0.10. The subscriber under the financing was MD Primer Inc., which is a control person of the Company. Dr. Anatoly Langer, the Company’s Chairman and acting CEO, is the majority shareholder of MD Primer Inc. For further information regarding the financing, please see the Company’s press release that was issued on March 22, 2010. The gross proceeds from the financing will be used for general working capital of the Company. The shares and warrants issued by the Company are subject to a four month hold period, which will expire on August 15, 2010.

The Company also announced that it has closed its previously announced settlement of an aggregate of \$81,250 of outstanding debt of the Company in exchange for the issuance of common shares. The debt represented accrued management fees for the fourth quarter of 2009. Allocations of shares were as follows: Dr. Anatoly Langer, the Company’s Chairman and interim CEO, received 750,000 shares representing \$37,500 of debt; Etienne Grima, the Company’s CFO and Secretary, received 500,000 shares representing \$25,000 of debt; and Healthcare Works Inc. which provides Chief Medical Officer services to the Company and is under the control or direction of Dr. Anatoly Langer, received 375,000 shares representing \$18,750 of debt. The shares issued by the Company are subject to a four month hold period, which will expire on July 30, 2010.

Upon completion of the private placement and the debt settlement, MD Primer Inc. holds 21,196,666 shares of the Company, representing approximately 34.8% of the Company’s outstanding shares, and 17,666,666 share purchase warrants of the Company. Dr. Langer holds or has control or direction over 30,923,081 shares, representing approximately 50.7% of the Company’s shares, and 17,666,666 warrants.

About CardioComm Solutions, Inc.

CardioComm’s patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company’s products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMST[™]) and GlobalCardio[™]. CardioComm’s software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

“Anatoly Langer”

Dr. Anatoly Langer, Chairman

For investor information, please contact:

Dr. Anatoly Langer

1.800.725.6585, ext. 264

www.cardiocommsolutions.com

*The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release*